Drug Trial Radar · NCT04788017
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Feb 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 24, 2021
Primary completion
Jun 14, 2021
Study completion Jul 22, 2021
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.
Conditions
- Healthy Subjects
Interventions
ZiresovirDrug
Planned treatments are: * Cohort 1: 300 mg of ziresovir * Cohort 2: up to 600 mg of ziresovir * Cohort 3: up to 900 mg of ziresovir
PlaceboOther
Planned treatments are: * Cohort 1: 300 mg of placebo * Cohort 2: up to 600 mg of placebo * Cohort 3: up to 900 mg of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- numbers of all AEsTime frame: through study completion, an average of 22 days
- percentages of all AEsTime frame: through study completion, an average of 22 days
- change from baseline in systolic and diastolic blood pressureTime frame: screen/day -1/day 1/day 2/day 3/day4
- change from baseline in pulse rateTime frame: screen/day -1/day 1/day 2/day 3/day4
- change from baseline in respiratory rateTime frame: screen/day -1/day 1/day 2/day 3/day4
- change from baseline in oral temperatureTime frame: screen/day -1/day 1/day 2/day 3/day4
- change from baseline in Prothrombin time/International Normalized RatioTime frame: screen/day -1/day 2/day4
- change from baseline in Thrombin timeTime frame: screen/day -1/day 2/day4
- change from baseline in activated Partial Thromboplastin timeTime frame: screen/day -1/day 2/day4
- change from baseline in Hemoglobin (Hgb) countTime frame: screen/day -1/day 2/day4
- change from baseline in Hematocrit (Hct)Time frame: screen/day -1/day 2/day4
- change from baseline in Platelet countTime frame: screen/day -1/day 2/day4
- change from baseline in Red blood cell (RBC) countTime frame: screen/day -1/day 2/day4
- change from baseline in White blood cell (WBC) count with differentialTime frame: screen/day -1/day 2/day4
- change from baseline in Specific gravity from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in pH from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Protein from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Glucose from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Ketones from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Bilirubin from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Blood from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Nitrites from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Leukocytes from urinalysisTime frame: screen/day -1/day 2/day4
- change from baseline in Urobilinogen from urinalysisTime frame: screen/day -1/day 2/day4
- Incidence of abnormal Microscopic urine analysisTime frame: screen/day -1/day 2/day4
- change from baseline in heart rate-corrected QT interval from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
- change from baseline in heart rate from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
- change from baseline in QRS intervals from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
- change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
- change from baseline in appearance of U-waves from resting 12-lead ECGsTime frame: screen/day -1/day1/day2/day4
- Incidence of abnormal physical findingsTime frame: screen/day -1/day2/day3/day4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Frontage
Secaucus, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.